President’s Letter | January 2022 From the Desk of Samantha Guild Happy 2022! I hope this year is joyful and healthy for you and…
President’s Letter | December 2021 From the Desk of Samantha Guild Here at AIM at Melanoma, we started 2021 talking about Hope and are ending…
President’s Letter | September 2021 From the Desk of Samantha Guild As I reviewed the articles for this month’s newsletter, I thought about the fact…
President’s Letter | July 2021 From the Desk of Samantha Guild I was struck several times this month with the idea that the fight against…
President’s Letter | May 2021 From the Desk of Samantha Guild This month’s newsletter is so chock-full it will be delivered in two parts: today…
President’s Letter | March 2021 From the Desk of Samantha Guild As you read this post, the U.S. and a lot of the world is…
President’s Letter | January 2021 From the Desk of Samantha Guild In a January newsletter it is traditional to wish you a happy new year…
President’s Letter | November 2020 From the Desk of Samantha Guild It’s hard to believe that we’re nearing the holiday season and the end of…
President’s Letter |September 2020 From the Desk of Samantha Guild The fall is upon us, and here at AIM at Melanoma, we’re busy with…
President’s Update June | 2020 June|2020 Greetings to the AIM at Melanoma community, Thank you for so many thoughtful acknowledgments and heartfelt tributes for my…
Jun. 23, 2026 Insights from the 2026 the American Academy of Dermatology (AAD) Annual Practice Safe Sun Survey
Jun. 09, 2026 The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public
Jun. 05, 2026 Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective